Market Overview

UPDATE: Morgan Stanley Reiterates on CVS/Caremark Following Acquisition of Coram

Share:
Related CVS
CVS Health Says Overdose-Reversal Drug Is Now Available Without A Prescription In Texas
Barron's Picks And Pans: Pharmacy-Benefit Managers, Mortgage Insurers And More
Focus On Quality For Long-Term Success (Seeking Alpha)

In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on CVS/Caremark Corporation (NYSE: CVS), but removed the $65.00 price target.

In the report, Morgan Stanley noted, “CVS' $2.1 billion acquisition of Coram, Apria's home infusion business should help solidify CVS' position in the HC continuum and in enhancing its relationships with health systems and ACOs in our view. Importantly, we don't think deal stands in way of supply chain/sourcing partnership.”

CVS/Caremark closed on Wednesday at $66.76.

Latest Ratings for CVS

DateFirmActionFromTo
Jun 2016Morgan StanleyDowngradesEqual-weight
May 2016JefferiesMaintainsBuy
May 2016CitigroupMaintainsNeutral

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!